{
    "nctId": "NCT00567190",
    "briefTitle": "A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer",
    "officialTitle": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 808,
    "primaryOutcomeMeasure": "Progression-Free Survival (PFS) Determined by an Independent Review Facility",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease, and candidate for chemotherapy. Participants with measurable and non-measurable disease are eligible (locally recurrent disease must not be amenable to resection with curative intent; participants with de novo Stage IV disease are eligible)\n* Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC)\n* Left ventricular ejection fraction (LVEF) \u226550 percent (%) at baseline (within 42 days of randomization)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n* For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective form of contraception and to continue its use for the duration of study treatment and for at least 7 months after the last dose of study treatment\n\nExclusion Criteria:\n\n* History of anti-cancer therapy for MBC (with the exception of one prior hormonal regimen for MBC, which must be stopped prior to randomization)\n* History of approved or investigative tyrosine kinase/HER inhibitors for breast cancer in any treatment setting, except trastuzumab used in the neoadjuvant or adjuvant setting\n* History of systemic breast cancer treatment in the neo-adjuvant or adjuvant setting with a disease-free interval from completion of the systemic treatment (excluding hormonal therapy) to metastatic diagnosis of less than (\\<)12 months\n* History of persistent Grade \u22652 hematologic toxicity resulting from previous adjuvant therapy\n* Current peripheral neuropathy of National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0, Grade \u22653 at randomization\n* History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent\n* Current clinical or radiographic evidence of central nervous system (CNS) metastases\n* Computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain is mandatory in cases of clinical suspicion of brain metastases\n* History of exposure to cumulative doses of anthracyclines\n* Current uncontrolled hypertension or unstable angina\n* History of congestive heart failure (CHF) of any New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (exception: atrial fibrillation or paroxysmal supraventricular tachycardia)\n* History of myocardial infarction within 6 months of randomization\n* History of LVEF decline to below 50% during or after prior trastuzumab neo-adjuvant or adjuvant therapy\n* Current dyspnea at rest due to complications of advanced malignancy, or other diseases that require continuous oxygen therapy\n* Inadequate organ function, as defined in the protocol, within 28 days prior to randomization\n* Current severe, uncontrolled systemic disease\n* Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment\n* Pregnant or lactating women\n* History of receiving any investigational treatment within 28 days of randomization\n* Current known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)\n* Receipt of IV antibiotics for infection within 14 days of randomization\n* Current chronic daily treatment with corticosteroids (excluding inhaled steroids)\n* Known hypersensitivity to any of the study drugs\n* Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}